Edition:
United Kingdom

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,304.00GBp
18 Dec 2017
Change (% chg)

9.00 (+0.69%)
Prev Close
1,295.00
Open
1,300.00
Day's High
1,314.50
Day's Low
1,296.50
Volume
9,237,765
Avg. Vol
10,405,911
52-wk High
1,724.50
52-wk Low
1,270.00

Latest Key Developments (Source: Significant Developments)

GlaxoSmithkLine Acquires Further 26 Pct Stake In Glaxo Saudi Arabia
9:19am GMT 

Dec 18 (Reuters) - GLAXOSMITHKLINE ::ACQUIRES ADDITIONAL 26 PERCENT STAKE IN GLAXO SAUDI ARABIA LIMITED‍​.INTENDS TO EXPAND PRODUCTION OF JEDDAH MANUFACTURE SITE BY 30 PERCENT IN NEXT 3 YEARS WITH MORE INVESTMENTS TO BE DONE BY 2020‍​.SAYS "ACQUISITION IS COMING ON TOP OF MORE THAN SAR 900 MILLION THAT GSK IS INVESTING IN ITS OPERATION IN SAUDI OVER NEXT 3 YEARS‍​".SAYS "BY INCREASING STAKE IN GSAL, GSK REITERATES COMMITMENT TO SUPPORT SAUDI GOVERNMENT PLANS TO DIVERSIFY ECONOMY ‍".  Full Article

Glaxosmithkline Submits Regulatory Application For Single-Dose Tafenoquine For Treatment Of Plasmodium Vivax Malaria
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Glaxosmithkline Plc ::SUBMITS REGULATORY APPLICATION FOR SINGLE-DOSE TAFENOQUINE FOR TREATMENT OF PLASMODIUM VIVAX MALARIA TO AUSTRALIA'S THERAPEUTIC GOODS ADMINISTRATION​.GSK PLANS TO PROGRESS REGULATORY FILINGS IN OTHER COUNTRIES IN 2018‍​.  Full Article

U.S. FDA Approves First Drug For Eosinophilic Granulomatosis With Polyangiitis
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - U.S. Food and Drug Administration::SAYS EXPANDED APPROVED USE OF NUCALA (MEPOLIZUMAB) TO TREAT ADULT PATIENTS WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS‍.SAYS GRANTED APPROVAL OF NUCALA TO GLAXOSMITHKLINE.  Full Article

Glaxosmithkline Says ‍New Data From Phase III Clinical Study Supports Safety And Efficacy
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Glaxosmithkline Plc ::‍NEW DATA FROM A PHASE III CLINICAL STUDY SUPPORTS SAFETY AND EFFICACY OF SHINGRIX IN PREVENTING SHINGLES​.ZOE-HSCT STUDY SUCCEEDED PRIMARY OBJECTIVE BY DEMONSTRATING AN EFFICACY OF 68.17% AGAINST SHINGLES IN SUBJECTS ABOVE 18 YEARS OF AGE​.  Full Article

ACCC Institutes Proceedings Against GSK, Novartis
Tuesday, 5 Dec 2017 

Dec 6 (Reuters) - Australian Competition and Consumer Commission:INSTITUTED PROCEEDINGS AGAINST GLAXOSMITHKLINE HEALTHCARE AUSTRALIA PTY LTD (GSK) AND NOVARTIS CONSUMER HEALTH AUSTRALASIA.PROCEEDINGS ALLEGING THEY MADE FALSE OR MISLEADING REPRESENTATIONS IN MARKETING OF VOLTAREN OSTEO GEL AND VOLTAREN EMULGEL PAIN RELIEF PRODUCTS.SEEKING DECLARATIONS, INJUNCTIONS, PECUNIARY PENALTIES, A PUBLICATION ORDER, THE IMPOSITION OF A COMPLIANCE PROGRAM AND COSTS.  Full Article

John Wood Group Wins Multi-Million Dollar Contract Supporting Glaxosmithkline In Germany​
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - John Wood Group Plc ::WOOD WINS CONTRACT SUPPORTING GLAXOSMITHKLINE.‍WOOD WINS MULTI-MILLION DOLLAR CONTRACT SUPPORTING GLAXOSMITHKLINE IN GERMANY​.  Full Article

Glaxosmithkline says ViiV Healthcare starts Phase 3 HIV prevention study in women
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - GLAXOSMITHKLINE PLC ::‍VIIV STARTS PHASE 3 HIV PREVENTION STUDY IN WOMEN​.‍VIIV HEALTHCARE, CO OWNED BY GSK, WITH PFIZER INC. AND SHIONOGI LTD AS SHAREHOLDERS, TO START PHASE III STUDY FOR PREVENTION OF HIV INFECTION IN SEXUALLY ACTIVE WOMEN​.  Full Article

GSK says submits US application for malaria drug
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - GLAXOSMITHKLINE PLC ::‍SUBMITS US REGULATORY APPLICATION FOR SINGLE-DOSE TAFENOQUINE FOR PLASMODIUM VIVAX MALARIA​.GSK.L - ‍TAFENOQUINE IS NOT APPROVED FOR USE ANYWHERE IN WORLD; PLANS TO PROGRESS REGULATORY FILINGS IN OTHER COUNTRIES IN 2017 AND 2018​.  Full Article

U.S. FDA approves Juluca, a two-drug regimen for certain patients with HIV
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - U.S. Food and Drug Administration::Approved Juluca, a fixed-dose tablet containing dolutegravir and rilpivirine, to treat adults with HIV-1 infections ‍​.Granted approval of Juluca to ViiV Healthcare​.  Full Article

GlaxoSmithKline says European Commission grants marketing authorisation for Trelegy Ellipta
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Glaxosmithkline Plc :TRELEGY ELLIPTA ONCE-DAILY SINGLE INHALER TRIPLE THERAPY GAINS MARKETING AUTHORISATION IN EUROPE FOR TREATMENT OF COPD​.  Full Article

Deals of the day-Mergers and acquisitions

Dec 18 The following bids, mergers, acquisitions and disposals were reported by 1430 GMT on Monday: